Skip to main content

Advertisement

SpringerLink
Log in

Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization

  • Clinical Investigation
  • Interventional Oncology
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Purpose

To investigate predictors of overall survival (OS) and progression-free survival (PFS) in patients with ocular melanoma metastatic to the liver undergoing yttrium-90 (Y90) radioembolization, including the effect of concurrent immunotherapy.

Methods

An IRB-approved retrospective review of 24 patients with ocular melanoma metastatic to the liver who underwent Y-90 treatment between June 2003 and January 2018 was performed. Data regarding patients’ performance status at the time of Y90, intra-/extrahepatic tumor burden, and treatment response were evaluated. RECIST was used to determine objective tumor response. Kaplan–Meier analysis was used to calculate OS and PFS from the first Y90 therapy. Log-rank analysis was used to determine predictors of prolonged OS and PFS.

Results

Median OS from primary diagnosis and diagnosis of liver metastases was 66 months (mo) and 26.3 mo, respectively. Median OS for those who received immunotherapy within 3 months of undergoing Y90 was prolonged at 26.0 mo versus 9.5 mo for others (p = 0.014). Median OS for patients with an ECOG performance status of 0 was prolonged at 26 mo versus 5.5 mo for others (p = 0.003). Median hepatic PFS was prolonged in patients treated with Y-90 on concurrent immunotherapy at 10.3 mo versus 2.7 mo for TARE only (p = 0.002). Patients with an ECOG performance status of 0 had prolonged PFS (p = 0.002).

Conclusions

Concurrent immunotherapy and an ECOG performance status of 0 at the time of Y90 therapy appear to be predictors of prolonged OS and PFS in patients with ocular melanoma metastatic to the liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Komatsubara KM, Carvajal RD. Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies. Curr Oncol Rep. 2017;19(7):45.

    Article  Google Scholar 

  2. Schelhorn J, Richly H, Ruhlmann M, Lauenstein TC, Theysohn JM. A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma. Acta Radiol Open. 2015;4(4):2047981615570417.

    PubMed  PubMed Central  Google Scholar 

  3. Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. 2011;196(2):468–73.

    Article  Google Scholar 

  4. Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Interv Radiol. 2013;36(1):158–65.

    Article  CAS  Google Scholar 

  5. Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer. 2016;122(15):2299–312.

    Article  Google Scholar 

  6. Page DB, Postow MA, Callahan MK, Wolchok JD. Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep. 2013;15(5):500–8.

    Article  CAS  Google Scholar 

  7. Gupta S, Bedikian AY, Ahrar J, et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol. 2010;33(5):474–80.

    Article  Google Scholar 

  8. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol. 2010;37(2):127–38.

    Article  Google Scholar 

  9. Xing M, Prajapati HJ, Dhanasekaran R, et al. Selective internal yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy: safety and efficacy cohort study. Am J Clin Oncol. 2017;40(1):27–34.

    Article  Google Scholar 

  10. Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined effects of yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series. J Vasc Interv Radiol. 2018;29(10):1369–75.

    Article  Google Scholar 

  11. Valsecchi ME, Terai M, Eschelman DJ, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol. 2015;26(4):523–32.

    Article  Google Scholar 

  12. Lane AM, Kim IK, Gragoudas ES. Survival rates in patients after treatment for metastasis from uveal melanoma. JAMA Ophthalmol. 2018;136(9):981–6.

    Article  Google Scholar 

  13. Gil-Alzugaray et al. (2017). SIR-spheres Y-90 resin microspheres (yttrium-90 microspheres). Retrieved from https://www.sirtex.com/media/155126/ssl-us-13.pdf. Accessed 1 Mar 2019.

  14. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–16.

    Article  CAS  Google Scholar 

  15. Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Am J Clin Oncol. 2012;35(2):167–77.

    Article  Google Scholar 

  16. Braat MN, van Erpecum KJ, Zonnenberg BA, van den Bosch MA, Lam MG. Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol. 2017;29(2):144–52.

    Article  CAS  Google Scholar 

  17. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–71.

    Article  CAS  Google Scholar 

  18. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5(2):403–16.

    Article  Google Scholar 

  19. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687–95.

    Article  CAS  Google Scholar 

  20. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–88.

    Article  CAS  Google Scholar 

  21. Itchins M, Ascierto PA, Menzies AM, et al. A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Res. 2017;27(3):243–50.

    Article  Google Scholar 

Download references

Funding

This study was not supported by any funding.

Author information

Authors and Affiliations

  1. Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image Guided Medicine, Emory University School of Medicine, Atlanta, USA

    Alexa O. Levey, Mohammad Elsayed, Robert M. Ermentrout, Zachary L. Bercu, Janice Newsome & Nima Kokabi

  2. Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, USA

    David H. Lawson, Ragini R. Kudchadkar & Melinda L. Yushak

Authors
  1. Alexa O. Levey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Elsayed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David H. Lawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert M. Ermentrout
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ragini R. Kudchadkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zachary L. Bercu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Melinda L. Yushak
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Janice Newsome
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nima Kokabi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Nima Kokabi, preceptor, conceived and designed the analysis. Alexa Levey and Mohammad Elsayed collected the data and performed the analysis. Alexa Levey wrote the paper. All authors discussed the results and contributed to the final manuscript.

Corresponding author

Correspondence to Nima Kokabi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this study, no formal consent is required. The study was approved by IRB.

Informed Consent

This study has obtained IRB approval (indicate the relevant board) and the need for informed consent was waived. For this type of study, consent for publication is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Levey, A.O., Elsayed, M., Lawson, D.H. et al. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization. Cardiovasc Intervent Radiol 43, 254–263 (2020). https://doi.org/10.1007/s00270-019-02366-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-019-02366-8

Keywords

Search

Navigation